NEKTAR THERAPEUTICS Insider Trading for November 2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NEKTAR THERAPEUTICS.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in NEKTAR THERAPEUTICS for November 2017.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Option Exercise | A | 14.41 | 37,500 | 540,375 | 37,500 | |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Sell | D | 44.23 | 5,289 | 233,932 | 60,549 | 65.8 K to 60.5 K (-8.03 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Grant | A | 0.00 | 15,000 | 0 | 65,838 | 50.8 K to 65.8 K (+29.51 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | A | 14.41 | 137,500 | 1,981,375 | 137,500 | |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | D | 44.23 | 18,069 | 799,192 | 189,435 | 207.5 K to 189.4 K (-8.71 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Grant | A | 0.00 | 55,000 | 0 | 207,504 | 152.5 K to 207.5 K (+36.06 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Option Exercise | A | 14.41 | 50,000 | 720,500 | 50,000 | |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Sell | D | 44.23 | 6,620 | 292,803 | 246,536 | 253.2 K to 246.5 K (-2.61 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Grant | A | 0.00 | 20,000 | 0 | 253,156 | 233.2 K to 253.2 K (+8.58 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Option Exercise | A | 14.41 | 50,000 | 720,500 | 50,000 | |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Sell | D | 44.23 | 6,698 | 296,253 | 76,716 | 83.4 K to 76.7 K (-8.03 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Grant | A | 0.00 | 20,000 | 0 | 83,414 | 63.4 K to 83.4 K (+31.54 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Option Exercise | A | 14.41 | 37,500 | 540,375 | 37,500 | |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Sell | D | 44.23 | 5,597 | 247,555 | 67,636 | 73.2 K to 67.6 K (-7.64 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Grant | A | 0.00 | 15,000 | 0 | 73,233 | 58.2 K to 73.2 K (+25.76 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Gergel Ivan P. | SVP & Chief Medical ... | Option Exercise | A | 14.41 | 50,000 | 720,500 | 50,000 | |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Gergel Ivan P. | SVP & Chief Medical ... | Sell | D | 44.23 | 5,022 | 222,123 | 56,553 | 61.6 K to 56.6 K (-8.16 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Gergel Ivan P. | SVP & Chief Medical ... | Grant | A | 0.00 | 20,000 | 0 | 61,575 | 41.6 K to 61.6 K (+48.11 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Option Exercise | A | 14.41 | 43,750 | 630,438 | 43,750 | |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Sell | D | 44.23 | 4,782 | 211,508 | 43,820 | 48.6 K to 43.8 K (-9.84 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Grant | A | 0.00 | 17,500 | 0 | 48,602 | 31.1 K to 48.6 K (+56.27 %) |
Nov 15 2017 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Option Exercise | M | 9.24 | 25,000 | 231,000 | 0 | |
Nov 15 2017 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Sell | S | 37.78 | 15,910 | 601,080 | 233,156 | 249.1 K to 233.2 K (-6.39 %) |
Nov 15 2017 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Buy | M | 9.24 | 25,000 | 231,000 | 249,066 | 224.1 K to 249.1 K (+11.16 %) |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Option Exercise | M | 10.69 | 17,300 | 184,937 | 0 | |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Option Exercise | M | 10.69 | 5,117 | 54,701 | 17,300 | |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Sell | M | 25.51 | 17,300 | 441,323 | 58,233 | 75.5 K to 58.2 K (-22.90 %) |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Buy | M | 10.69 | 17,300 | 184,937 | 75,533 | 58.2 K to 75.5 K (+29.71 %) |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Sell | S | 25.07 | 5,117 | 128,283 | 58,233 | 63.4 K to 58.2 K (-8.08 %) |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Buy | M | 10.69 | 5,117 | 54,701 | 63,350 | 58.2 K to 63.4 K (+8.79 %) |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Option Exercise | M | 9.53 | 300,000 | 2,859,000 | 0 | |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Option Exercise | M | 9.53 | 75,409 | 718,648 | 300,000 | |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Option Exercise | M | 9.53 | 20,914 | 199,310 | 375,409 | |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Sell | S | 30.09 | 300,000 | 9,027,000 | 31,102 | 331.1 K to 31.1 K (-90.61 %) |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Buy | M | 9.53 | 300,000 | 2,859,000 | 331,102 | 31.1 K to 331.1 K (+964.57 %) |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Sell | S | 25.78 | 75,409 | 1,944,044 | 31,102 | 106.5 K to 31.1 K (-70.80 %) |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Buy | M | 9.53 | 75,409 | 718,648 | 106,511 | 31.1 K to 106.5 K (+242.46 %) |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Sell | S | 24.98 | 20,914 | 522,432 | 31,102 | 52 K to 31.1 K (-40.21 %) |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Buy | M | 9.53 | 20,914 | 199,310 | 52,016 | 31.1 K to 52 K (+67.24 %) |
Nov 03 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | M | 11.34 | 83,334 | 945,008 | 166,666 | |
Nov 03 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 23.57 | 83,334 | 1,964,182 | 152,504 | 235.8 K to 152.5 K (-35.34 %) |
Nov 03 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Buy | M | 11.34 | 83,334 | 945,008 | 235,838 | 152.5 K to 235.8 K (+54.64 %) |